Long-term follow-up study of SAT-3247 for Duchenne muscular dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study follows people with Duchenne muscular dystrophy who were in an earlier SAT-3247 trial, or who meet certain other criteria, to see how the medicine works over a longer time. It aims to gather more safety and effectiveness information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in the earlier SAT-3247 study (Group A) or meet other specific criteria (Group B).
- Your steroid dose (like prednisone or deflazacort) must be stable or you must not be taking steroids.
- Your other medicines and supplements must be at a stable dose.
- You must be able to swallow tablets (or take them crushed or split in food).
- You must not have severe behavioral or cognitive problems that would prevent participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
This long-term study continues to test an experimental treatment for Duchenne muscular dystrophy that works by helping the body skip over faulty parts of the gene. It is only open to people who already finished one of the earlier studies of this drug, to see if it remains safe and effective over a longer time.
This study tests whether a new medicine called zeleciment rostudirsen can help ambulatory (walking) males with Duchenne muscular dystrophy (DMD). The medicine is given as an intravenous infusion (through a vein) every 4 weeks and works by helping the body produce a protective muscle protein.
This trial tests a new medicine called ENTR-601-44 for people with Duchenne muscular dystrophy whose genetic mutation can be treated by skipping a part of the gene called exon 44. The goal is to see if it is safe and helps with muscle function.
This trial tests an experimental drug called ENTR-601-45 for people with Duchenne muscular dystrophy that can be treated with 'exon 45 skipping.' The goal is to see if it's safe and helps improve muscle function. It's for males between 4 and 20 who can still walk and have enough arm strength.
This study checks how people with Duchenne muscular dystrophy are doing long-term after receiving delandistrogene moxeparvovec (SRP-9001) in an earlier trial. It helps researchers understand the long-term safety and effects of that treatment.
Hear when a new Duchenne Muscular Dystrophy (DMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.